Business Context and Reporting Period
This Form 8-K was filed by TherapeuticsMD, Inc. on July 24, 2022. The report details a material definitive agreement regarding the company's financing structure and the appointment of a Chief Restructuring Officer.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data. Specific financial figures disclosed include:
- Interest Payment: The Company agreed to pay approximately $2.9 million in interest to lenders under the amended Financing Agreement.
- Debt Maturity: The maturity date of the Financing Agreement was amended to July 27, 2022.
Material Changes
The primary material change reported is the execution of Amendment No. 13 to the Financing Agreement dated April 24, 2019, with Sixth Street Specialty Lending, Inc. and various lenders. Key changes include:
- Extension of the debt maturity date to July 27, 2022.
- Commitment to an immediate interest payment of approximately $2.9 million.
- Retention of Jeffrey Varsalone from G2 Capital Advisors as Chief Restructuring Officer (CRO).
Outlook, Risks, and Management Commentary
Management is actively evaluating options to strengthen the capital structure and financial position. These options include potential refinancing, other strategic alternatives, and the possibility of filing for Chapter 11 bankruptcy protection. The company intends to maintain normal operations during this evaluation.
Significant risks and contingencies identified include:
- Going Concern: Uncertainty regarding the ability to refinance indebtedness and continue as a going concern.
- Liquidity: Challenges in raising capital to fund operations.
- Operational Risks: Supply chain issues, product liability lawsuits, and reliance on third-party manufacturers.
- Commercialization: Risks associated with the development and commercialization of products including IMVEXXY, ANNOVERA, and BIJUVA.
Investor Verification Checklist
- Verify the company's ability to refinance the term loan facility maturing on July 27, 2022.
- Monitor announcements regarding a potential Chapter 11 bankruptcy filing or other strategic alternatives.
- Assess the impact of the $2.9 million interest payment on current liquidity.
- Review the progress of the restructuring strategy led by the newly appointed Chief Restructuring Officer.